Evommune, Inc. EVMN
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria ("CSU"), atopic dermatitis ("AD") and ulcerative colitis ("UC"). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients' quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $13.0M | $7.0M | — |
| R&D | $74.0M | $64.2M | — |
| SG&A | $20.0M | $12.8M | — |
| Total operating expenses | $94.1M | $77.0M | — |
| Operating income | -$81.1M | -$70.0M | — |
| Pre-tax income | -$68.9M | -$68.3M | — |
| Income tax | $0 | $0 | — |
| Net income | -$68.9M | -$66.8M | — |
| EPS, basic | -11.22 | -45.29 | — |
| EPS, diluted | -11.22 | -45.29 | — |
| Shares, diluted (wtd. avg.) | 6.1M | 1.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | $44.1M | $16.3M | $29.2M |
| Short-term investments | $105.1M | $55.8M | — |
| Total current assets | $153.5M | $74.0M | — |
| Property, plant and equipment | $994.0K | $1.3M | — |
| Total assets | $224.9M | $76.1M | — |
| Accounts payable | $7.8M | $8.3M | — |
| Total current liabilities | $17.9M | $28.0M | — |
| Total liabilities | $19.4M | $28.5M | — |
| Retained earnings | -$221.1M | -$152.2M | — |
| Total equity | $205.6M | -$144.2M | -$77.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$76.4M | -$58.2M | — |
| Depreciation and amortisation | $600.0K | $500.0K | — |
| Stock-based compensation | $5.9M | $1.7M | — |
| Capital expenditure | $235.0K | $88.0K | — |
| Investing cash flow | -$115.3M | -$4.0M | — |
| Financing cash flow | $220.8M | $49.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-093932.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | $7.0M | $13.0M |
| Gross profit | — | — | — |
| Net income | — | -$66.8M | -$68.9M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |